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Background
Compared to adults, children are likely to spend longer
on antiretroviral treatment (ART), particularly if ART is
started in infancy, and may respond differently to PTIs
due to higher thymic activity.
Methods
PENTA 11 was a Phase II randomised trial to compare
CD4-guided PTI with continuous therapy (CT) in children
with confirmed viral load (VL) <50 c/ml, and CD4%
≥30% (ages 2–6 years) or CD4% ≥25% and CD4 ≥500
cells/mm3 (7–15 years). In the PTI arm, ART was restarted
if confirmed CD4% <20% (<7 years) or CD4% <20% or
CD4 <350 cells/mm3 (≥7 years). Additional precautions
were subsequently added; duration of a PTI should not
exceed 48 weeks and further PTIs undertaken only in chil-
dren who spent >10 weeks off ART during 1st PTI and had
been back on ART for 24 weeks. The primary end-point
was CD4% <15% (and CD4 <200 cells/mm3 ≥7 years), or
CDC C event or death. Children were followed until the
last randomised child completed 72 weeks follow-up. All
comparisons were intention-to-treat.
Summary of results
From 2004 to 2006, 109 children from nine countries
were randomised to CT (53) or PTI (56): 45% male,
median age 9 (range 2–16) years; 35% white, 31% black;
26% CDC stage C, median time on ART 6 years. Median
baseline CD4% was 37% (IQR: 33,41), CD4 966
(793,1258) cells/mm3; prior to ART nadir CD4% 18%
(10,27) and CD4 627 (320,1050) cells/mm3. After
median 130 (80,144) weeks follow-up (one child lost),
4% of time was spent off ART in CT vs. 48% in PTI. On 1st
PTI 21 (38%) children restarted ART before 48 weeks (14
protocol, seven other reasons); 32 (57%) restarted at 48
weeks and three remained off ART. 16 children had a 2nd
PTI. No child died or had a CDC C event; 1 CT vs. 4 PTI
children had a CD4 end-point (p = 0.4); 98.4% vs. 95.9%
of time was spent with CD4 ≥350 cells/mm3. Mean CD4
change from 0–72 weeks was -106 vs. -240 cells/mm3 in
CT vs. PTI (difference -134 cells/mm3, 95% CI -237, -31,
p = 0.01; six children were off ART in PTI). However, mean
CD4 change 0–72 weeks was -124 cells/mm3 in 27 chil-
dren in the PTI arm who had been back on ART for ≥24
weeks. In the PTI arm CD4 recovery adjusted for age
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appeared better in younger children (CD4 z-score change
from 0–24 weeks after restarting -0.1, -0.9, -1.3 for ages 2–
6, 7–10 and 11+ years, respectively, p = 0.02). At 72
weeks, 94%/85% vs. 81%/58% children had VL <400/<50
c/ml in CT vs PTI (p = 0.04/0.002). Of the 28 PTI children
back on ART for ≥24 weeks, 89%/68% had VL <400/<50
c/ml.
Conclusion
In summary, PENTA 11 was the first randomised trial of
planned treatment interruptions (PTIs) in children with
chronic HIV infection. In this pilot study we observed no
deaths or serious clinical events. Overall, fewer PTI chil-
dren were suppressed <50 c/ml at 72 weeks (analysis of
resistance results is ongoing) and CD4 recovery after PTI
appeared better in younger children. However, longer-
term assessment of all children after restarting ART will be
required to fully assess risks and benefits of PTI in this
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